Almac Clinical Services

Insmed Incorporated is a biopharmaceutical company focused on development and commercialization of drug formulations for treatment of metabolic diseases and endocrine disorders. The company, located in Glen Allen, Va., focuses on correcting metabolic defects in human body by replacing key proteins physiologically. It develops drugs that modulate insulin-like growth factor-1 activity in human body. Insmed Incorporated offers various drug candidates, such as recombinant human IGF-1 bound to protein-3, and IPLEX, which is mecasermin rinfabate injection for treatment of growth failure in children with severe IGF-I deficiency. The company also offers anti-cancer drugs, such as recombinant human insulin-like growth factor binding protein-3, and INSM-18. It develops drugs to treat indications in metabolic and oncology fields.

Almac Clinical Technologies specializes in the use of technology and project management to accelerate clinical trials, increase data quality and reduce trial costs. The company is a division of Almac Group. Almac Group is a provider of research and development and manufacturing services to more than 600 companies. The company operates several business units, including Almac Diagnostics, Almac Sciences, Almac Clinical Services, Almac Clinical Technologies and Almac Pharma Services. Almac Diagnostics develops, markets and supplies diagnostic products. Almac Sciences provides chemistry solutions and products that support drug discovery, development and commercialization. Almac Clinical Services provides services relating to the manufacture, packaging, labeling, release, distribution, return and analysis of supplies used in clinical trials. Almac Pharma Services provides formulation development, commercial-scale manufacturing services and distribution of pharmaceutical products. Almac Clinical Technologies is headquartered in Yardley, Penn.